Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy
Anand Rotte, Jiangtao Jin, Vincent Lemaire
Annals of Oncology (2017) Vol. 29, Iss. 1, pp. 71-83
Open Access | Times Cited: 319

Showing 1-25 of 319 citing articles:

Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 826
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3
Jun Wang, Miguel F. Sanmamed, Ila Datar, et al.
Cell (2018) Vol. 176, Iss. 1-2, pp. 334-347.e12
Open Access | Times Cited: 712
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
Wenfeng Fang, Yunpeng Yang, Yuxiang Ma, et al.
The Lancet Oncology (2018) Vol. 19, Iss. 10, pp. 1338-1350
Closed Access | Times Cited: 417
PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
Arash Salmaninejad, Saeed Farajzadeh Valilou, Arezoo Gowhari Shabgah, et al.
Journal of Cellular Physiology (2019) Vol. 234, Iss. 10, pp. 16824-16837
Closed Access | Times Cited: 383
Immune checkpoint therapy in liver cancer
Feng Xu, Tianqiang Jin, Yuwen Zhu, et al.
Journal of Experimental & Clinical Cancer Research (2018) Vol. 37, Iss. 1
Open Access | Times Cited: 340
Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities
Beate Bittner, W. Richter, Johannes Schmidt
BioDrugs (2018) Vol. 32, Iss. 5, pp. 425-440
Open Access | Times Cited: 324
Metal Drugs and the Anticancer Immune Response
Bernhard Englinger, Christine Pirker, Petra Heffeter, et al.
Chemical Reviews (2018) Vol. 119, Iss. 2, pp. 1519-1624
Open Access | Times Cited: 305
Enhancing anti-tumour efficacy with immunotherapy combinations
Funda Meric‐Bernstam, James Larkin, Josep Tabernero, et al.
The Lancet (2020) Vol. 397, Iss. 10278, pp. 1010-1022
Closed Access | Times Cited: 305
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Xin Wang, Gaochao Guo, Hui Guan, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 237
Patterns of Response and Progression to Immunotherapy
Édith Borcoman, Amara Nandikolla, Georgina V. Long, et al.
American Society of Clinical Oncology Educational Book (2018), Iss. 38, pp. 169-178
Closed Access | Times Cited: 230
Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T
Dok Hyun Yoon, Mark J. Osborn, Jakub Tolar, et al.
International Journal of Molecular Sciences (2018) Vol. 19, Iss. 2, pp. 340-340
Open Access | Times Cited: 198
Single-cell RNA sequencing reveals the tumor microenvironment and facilitates strategic choices to circumvent treatment failure in a chemorefractory bladder cancer patient
Hye Won Lee, Woosung Chung, Hae‐Ock Lee, et al.
Genome Medicine (2020) Vol. 12, Iss. 1
Open Access | Times Cited: 156
Cancer Vaccines, Adjuvants, and Delivery Systems
Samantha Paston, Victoria A. Brentville, Peter Symonds, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 145
Understanding LAG-3 Signaling
Luisa Chocarro, Ester Blanco, Miren Zuazo, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 10, pp. 5282-5282
Open Access | Times Cited: 139
Immunotherapy in Melanoma: Recent Advances and Future Directions
Andrew Knight, Lilit Karapetyan, John M. Kirkwood
Cancers (2023) Vol. 15, Iss. 4, pp. 1106-1106
Open Access | Times Cited: 123
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
Kenneth K.W. To, Winnie Fong, William C. Cho
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 111
Regulatory mechanisms of PD-1/PD-L1 in cancers
Xin Lin, Kuan Kang, Pan Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 111
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Jim Middelburg, Kristel Kemper, Patrick Engelberts, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 287-287
Open Access | Times Cited: 105
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
Rebecca Simpson, Erin R. Shanahan, Richard A. Scolyer, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 10, pp. 697-715
Closed Access | Times Cited: 54
Tumour immune rejection triggered by activation of α2-adrenergic receptors
Jingjing Zhu, Stefan Naulaerts, Loubna Boudhan, et al.
Nature (2023) Vol. 618, Iss. 7965, pp. 607-615
Closed Access | Times Cited: 47
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
Huageng Huang, Yuyi Yao, Xinyi Deng, et al.
International Journal of Oncology (2023) Vol. 63, Iss. 2
Open Access | Times Cited: 47
Medical gas plasma technology: Roadmap on cancer treatment and immunotherapy
Sander Bekeschus
Redox Biology (2023) Vol. 65, pp. 102798-102798
Open Access | Times Cited: 44
Cancer Nanovaccines: Nanomaterials and Clinical Perspectives
Nimeet Desai, Vivek P. Chavda, Thakur Raghu Raj Singh, et al.
Small (2024) Vol. 20, Iss. 35
Open Access | Times Cited: 24
How to differentiate pseudoprogression from true progression in cancer patients treated with immunotherapy.
Yiming Ma, Qiwei Wang, Qian Dong, et al.
PubMed (2019) Vol. 9, Iss. 8, pp. 1546-1553
Closed Access | Times Cited: 132
TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
Brenda De Keersmaecker, Sofie Claerhout, Javier Carrasco, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000329-e000329
Open Access | Times Cited: 128
Page 1 - Next Page

Scroll to top